X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1601) 1601
animals (1348) 1348
female (924) 924
rank ligand - metabolism (870) 870
mice (847) 847
male (809) 809
osteoporosis (626) 626
rankl (562) 562
osteoprotegerin (544) 544
denosumab (522) 522
osteoclasts - drug effects (514) 514
receptor activator (468) 468
osteoclasts - metabolism (457) 457
rank ligand (399) 399
differentiation (394) 394
osteoclastogenesis (391) 391
expression (390) 390
middle aged (379) 379
osteoclasts (349) 349
rank ligand - genetics (343) 343
endocrinology & metabolism (342) 342
osteoclast (338) 338
trance protein (333) 333
osteoclasts - cytology (332) 332
bone resorption (329) 329
rank ligand - antagonists & inhibitors (322) 322
cell differentiation - drug effects (309) 309
cells, cultured (309) 309
bone density conservation agents - therapeutic use (307) 307
antibodies, monoclonal - therapeutic use (297) 297
osteoprotegerin - metabolism (297) 297
cell biology (292) 292
musculoskeletal diseases (289) 289
antibodies, monoclonal, humanized (286) 286
bone (282) 282
analysis (280) 280
cells (275) 275
aged (274) 274
oncology (269) 269
postmenopausal women (267) 267
gene expression (262) 262
rats (258) 258
adult (257) 257
mice, inbred c57bl (253) 253
cytokines (251) 251
inflammation (249) 249
signal transduction (246) 246
osteoclast differentiation (243) 243
rank ligand - pharmacology (241) 241
bone neoplasms - secondary (235) 235
kappa-b ligand (233) 233
rheumatology (233) 233
pharmacology & pharmacy (231) 231
diphosphonates - therapeutic use (230) 230
bone loss (223) 223
osteogenesis - drug effects (219) 219
orthopedics (216) 216
research article (216) 216
osteoclasts - pathology (208) 208
bone density - drug effects (207) 207
bones (206) 206
dentistry (206) 206
osteoporosis - drug therapy (206) 206
proteins (201) 201
activation (200) 200
rank ligand - therapeutic use (200) 200
research (200) 200
nf-kappa-b (199) 199
osteoblasts - metabolism (194) 194
signal transduction - drug effects (192) 192
rheumatoid-arthritis (191) 191
rank (189) 189
immunology (186) 186
zoledronic acid (186) 186
biocompatibility (185) 185
cancer (184) 184
receptor activator of nuclear factor-kappa b (184) 184
bone resorption - drug therapy (183) 183
disease models, animal (182) 182
dentistry, oral surgery & medicine (181) 181
bone resorption - metabolism (180) 180
medicine (179) 179
health aspects (178) 178
cell differentiation (177) 177
nf-kappa b - metabolism (177) 177
osteoblasts (176) 176
ligands (174) 174
rheumatoid arthritis (173) 173
biochemistry & molecular biology (172) 172
medicine & public health (172) 172
bone density (171) 171
in-vitro (171) 171
bone and bones - metabolism (169) 169
bone-resorption (168) 168
osteoclasts - physiology (167) 167
arthritis (166) 166
receptor activator of nuclear factor-kappa b - metabolism (166) 166
disease (165) 165
biomedical materials (164) 164
osteoblasts - drug effects (161) 161
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2395) 2395
Japanese (86) 86
French (11) 11
German (11) 11
Chinese (9) 9
Spanish (6) 6
Hungarian (5) 5
Danish (4) 4
Polish (4) 4
Italian (3) 3
Portuguese (2) 2
Russian (2) 2
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Norwegian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
...B ligand, on bone mineral density and fractures in such men. Use of denosumab was associated with increased bone mineral density at all sites and reduction in the incidence of new vertebral fractures... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 05/2016, Volume 11, Issue 5, p. e0154680
The receptor-activator of nuclear kappaB ligand (RANKL) signaling pathway plays an important role in the regulation of bone growth and mediates the formation and activation of osteoclasts... 
GIANT-CELL TUMOR | DENOSUMAB | MULTIDISCIPLINARY SCIENCES | Osteosarcoma - drug therapy | RANK Ligand - metabolism | Humans | Male | Antineoplastic Agents - therapeutic use | Fibrous Dysplasia of Bone - drug therapy | RNA, Messenger - metabolism | Bone Neoplasms - pathology | Giant Cell Tumor of Bone - pathology | Chondrosarcoma - genetics | Chondrosarcoma - pathology | Bone Cysts, Aneurysmal - metabolism | Bone Neoplasms - genetics | Fibrous Dysplasia of Bone - genetics | Chondroma - drug therapy | Osteoclasts - pathology | Bone Cysts, Aneurysmal - pathology | Multiple Myeloma - genetics | Osteosarcoma - pathology | Bone Cysts, Aneurysmal - drug therapy | Chondroma - genetics | Gene Expression Regulation, Neoplastic | Chondroma - metabolism | Chondroma - pathology | Bone Neoplasms - metabolism | Denosumab - therapeutic use | Multiple Myeloma - drug therapy | Giant Cell Tumor of Bone - drug therapy | RNA, Messenger - antagonists & inhibitors | Female | Bone Neoplasms - drug therapy | Giant Cell Tumor of Bone - genetics | Osteosarcoma - metabolism | Fibrous Dysplasia of Bone - pathology | RNA, Messenger - genetics | Multiple Myeloma - metabolism | Organ Specificity | Chondrosarcoma - drug therapy | Fibrous Dysplasia of Bone - metabolism | Osteoclasts - metabolism | Bone Resorption - prevention & control | RANK Ligand - genetics | Multiple Myeloma - pathology | Giant Cell Tumor of Bone - metabolism | RANK Ligand - antagonists & inhibitors | Chondrosarcoma - metabolism | Osteosarcoma - genetics | Osteoclasts - drug effects | Bone Cysts, Aneurysmal - genetics | Bone resorption | Bones | Dosage and administration | Denosumab | Growth | Analysis | Immunohistochemistry | Chondrosarcoma | Multiple myeloma | Aneurysm | Bone tumors | Metastasis | Bone surgery | Metastases | Osteoprotegerin | Ewings sarcoma | Signal transduction | Bone growth | Biomedical materials | Osteosarcoma | Fibrous dysplasia | Bone dysplasia | Biocompatibility | Lesions | TRANCE protein | University graduates | Statistical analysis | Bone lesions | Gene expression | Osteoclastogenesis | Signaling | Bone cancer | Hospitals | Biopsy | Stromal cells | Orthopedics | Monoclonal antibodies | Ligands | Osteoclasts | Prostate cancer | Tumors
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9773, pp. 1276 - 1287
... to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | SCLEROSTIN ANTIBODY | BONE-MINERAL DENSITY | CALCIUM-SENSING RECEPTOR | HUMAN OSTEOBLASTIC CELLS | OSTEOPROTEGERIN LIGAND | CATHEPSIN-K INHIBITOR | STRONTIUM RANELATE | VERTEBRAL FRACTURE | HEALTHY POSTMENOPAUSAL WOMEN | FRACTURE RISK | Wnt Proteins - drug effects | Vitamin D Deficiency - complications | Calcium - metabolism | Bone Morphogenetic Proteins - immunology | Humans | Middle Aged | Osteoporosis - diagnosis | Osteoporosis, Postmenopausal - metabolism | Antibodies, Monoclonal - therapeutic use | Osteoporosis - drug therapy | Wnt Proteins - metabolism | Biphenyl Compounds - therapeutic use | Osteoporosis - etiology | Bone Remodeling - drug effects | Antibodies, Monoclonal, Humanized | Osteoporosis - metabolism | Vitamin D Deficiency - therapy | Aged, 80 and over | Bone Resorption - metabolism | Diphosphonates - therapeutic use | Female | Benzodioxoles - therapeutic use | RANK Ligand - therapeutic use | Anabolic Agents - therapeutic use | Osteoporosis - prevention & control | Risk Assessment | Osteoporotic Fractures - prevention & control | Risk Factors | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Denosumab | Absorptiometry, Photon | Genetic Markers - immunology | Osteoclasts - metabolism | Osteoporosis, Postmenopausal - drug therapy | Randomized Controlled Trials as Topic | Bone Density - drug effects | Quinazolines - therapeutic use | Aged | Osteoblasts - metabolism | Intercellular Signaling Peptides and Proteins - immunology | Osteoporosis | Complications and side effects | Care and treatment | Diagnosis | Bones | Vitamin D | Womens health | Metabolic disorders | Cathepsin K | Cytokines | Proteinase | Socio-economic aspects | SOST protein | Osteoblasts | Post-menopause | Bone resorption | NF- Kappa B protein | Bone mass | Fractures | Reviews | Aging | Monoclonal antibodies | Osteoclasts | Dkk1 protein | Osteogenesis | Communication
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9768, pp. 813 - 822
Journal Article
Vascular Pharmacology, ISSN 1537-1891, 2016, Volume 82, pp. 30 - 40
.... In this respect, receptor activator of NF-κB ligand (RANKL) promotes VC whilst osteoprotegerin (OPG) acts as a RANKL decoy receptor to block this effect, events that contrast with the known functional influence of these proteins during bone metabolism... 
Cardiovascular | Vascular calcification | RANKL | TRAIL | Type-2 diabetes mellitus | OPG | SERUM OSTEOPROTEGERIN | AORTIC CALCIFICATION | PLASMA OSTEOPROTEGERIN | APOPTOSIS-INDUCING LIGAND | CORONARY-ARTERY CALCIFICATION | RECEPTOR ACTIVATOR | OSTEOCLASTIC DIFFERENTIATION | PHARMACOLOGY & PHARMACY | SMOOTH-MUSCLE-CELLS | CHRONIC KIDNEY-DISEASE | KAPPA-B LIGAND | RANK Ligand - metabolism | Humans | Diabetic Angiopathies - etiology | Arteries - metabolism | Atherosclerosis - etiology | Vascular Calcification - metabolism | Diabetic Angiopathies - pathology | Vascular Calcification - etiology | Osteoprotegerin - therapeutic use | Diabetes Mellitus, Type 2 - complications | Diabetic Angiopathies - metabolism | Atherosclerosis - pathology | Osteoclasts - pathology | Atherosclerosis - drug therapy | Signal Transduction | Osteogenesis - drug effects | Arteries - drug effects | Arteries - pathology | Diabetic Angiopathies - drug therapy | Vascular Calcification - drug therapy | Plaque, Atherosclerotic | TNF-Related Apoptosis-Inducing Ligand - metabolism | Vascular Calcification - pathology | Osteoclasts - metabolism | TNF-Related Apoptosis-Inducing Ligand - therapeutic use | Atherosclerosis - metabolism | Cardiovascular Agents - therapeutic use | Osteoblasts - pathology | Animals | RANK Ligand - antagonists & inhibitors | Osteoprotegerin - metabolism | Osteoblasts - metabolism | Type 2 diabetes | Analysis | Atherosclerosis | Venture capital | Physiological aspects | Calcification | Cardiovascular diseases | Health aspects
Journal Article